Skip to main content

Table 3 Comparison of mfERG parameters (P1) at the baseline and final examination (6th month)

From: Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical results

RingP1 amplitude (nv/deg2)P1 implict time (ms)
BaselineFinalP value%95 CI (L, U)BaselineFinalP value95% CI (L, U)
X ± SDX ± SDX ± SDX ± SD
124,77 ± 17,8739,77 ± 21,190,01*(−21,61,-8,38)44,17 ± 10,9132,36 ± 10,220,01*(−21,61,-8,38)
26,78 ± 4,313,62 ± 9,090,01*(−10,02,-3,65)45,17 ± 8,4733,22 ± 9,840,02*(−10,02,-3,65)
33,11 ± 3,865,68 ± 4,890,02*(−3,76,-1,38)41,99 ± 10,7732,4 ± 11,470,01*(−3,76,-1,38)
42,03 ± 1,372,74 ± 2,790,11(−1,6,0,17)47,31 ± 6,2247,31 ± 6,220,26(−1,6,0,17)
51,06 ± 0,841,13 ± 1,230,66(−0,38,0,24)48,49 ± 6,1448,37 ± 6,680,47(−0,38,0,24)
  1. X, mean values obtained from 34 eyes (32 patients); SD standard deviation;
  2. %95 CI L and U, 95% confidence interval of the difference (mean)
  3. * Bold: Significant p values and related data (i.e., coefficient and standard error) are set in italics